| Date Filed | Type | Description |
| 02/13/2019 |
SC 13G/A
| Capital International Investors reports a 0% stake in Juno Therapeutics Inc. |
| 04/16/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 03/16/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/06/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/06/2018 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 03/05/2018 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 03/05/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/05/2018 |
SC 13D/A
| CELGENE CORP reports a 85.4% stake in JUNO THERAPEUTICS, INC. |
| 03/05/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/01/2018 |
10-K
| Annual Report for the period ended December 31, 2017 |
| 02/22/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
| 02/22/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/21/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/21/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/21/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
| 02/21/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/20/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/20/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/14/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/14/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
| 02/09/2018 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.1% stake in Juno Therapeutics Inc |
| 02/07/2018 |
SC 13D/A
| BRATTON DOUGLAS K reports a 4.7% stake in Juno Therapeutics, Inc. |
| 02/02/2018 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 02/02/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
| 02/02/2018 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 02/02/2018 |
SC 13G/A
| Arch Venture Fund VII LP reports a 9.3% stake in Juno Therapeutics, Inc. |
| 02/01/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2018 |
GN
| New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan — Factors of Influence, Major Initiatives and Sustained Production |
|